MX365551B - Proteinas de fusion de apelina y usos de estas. - Google Patents

Proteinas de fusion de apelina y usos de estas.

Info

Publication number
MX365551B
MX365551B MX2015011350A MX2015011350A MX365551B MX 365551 B MX365551 B MX 365551B MX 2015011350 A MX2015011350 A MX 2015011350A MX 2015011350 A MX2015011350 A MX 2015011350A MX 365551 B MX365551 B MX 365551B
Authority
MX
Mexico
Prior art keywords
apelin
domain
fusion polypeptides
fusion proteins
aplnr
Prior art date
Application number
MX2015011350A
Other languages
English (en)
Other versions
MX2015011350A (es
Inventor
Panayiotis Stevis
Gromada Jesper
Murphy Andrew
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2015011350A publication Critical patent/MX2015011350A/es
Publication of MX365551B publication Critical patent/MX365551B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención se refiere a un polipéptido o proteína de fusión que comprende un péptido apelina fusionado a un componente de multimerización. La invención también proporciona un polipéptido o proteína de fusión que comprende un péptido apelina fusionado a un dominio Fc, un fragmento de un dominio Fc o una variante de un dominio Fc. Los polipéptidos de fusión Apelina Fc son capaces de unirse al receptor de apelina (APLNR). Los polipéptidos de fusión a apelina Fc pueden activar la APLNR y presentan mejores propiedades farmacocinéticas en comparación con los péptidos apelina que no se fusionan con un Fc o fragmento de Fc. Los polipéptidos de fusión a apelina Fc son útiles en enfermedades y afecciones relacionadas con la función cardiovascular, diabetes, cáncer, obesidad y otras afecciones relacionadas con apelina.
MX2015011350A 2013-03-14 2014-03-14 Proteinas de fusion de apelina y usos de estas. MX365551B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786172P 2013-03-14 2013-03-14
US201361906567P 2013-11-20 2013-11-20
PCT/US2014/028384 WO2014152955A1 (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
MX2015011350A MX2015011350A (es) 2016-01-15
MX365551B true MX365551B (es) 2019-06-07

Family

ID=50680161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011350A MX365551B (es) 2013-03-14 2014-03-14 Proteinas de fusion de apelina y usos de estas.

Country Status (16)

Country Link
US (3) US9353163B2 (es)
EP (1) EP2970415B1 (es)
JP (1) JP6525951B2 (es)
KR (1) KR20150127596A (es)
CN (1) CN105026423A (es)
AU (1) AU2014236451B2 (es)
BR (1) BR112015020587A2 (es)
CA (1) CA2904731A1 (es)
EA (1) EA201591700A1 (es)
ES (1) ES2708957T3 (es)
HK (1) HK1220466A1 (es)
IL (1) IL240587A0 (es)
MX (1) MX365551B (es)
SG (1) SG11201506335YA (es)
WO (1) WO2014152955A1 (es)
ZA (1) ZA201505927B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506335YA (en) 2013-03-14 2015-09-29 Regeneron Pharma Apelin fusion proteins and uses thereof
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
MA39061A1 (fr) 2013-11-20 2017-10-31 Regeneron Pharma Modulateurs d'aplnr et leurs utilisations
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
EP4257152A3 (en) 2014-06-10 2023-12-06 Amgen Inc. Apelin polypeptides
WO2016061141A1 (en) * 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
US9585934B2 (en) * 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
EP3237435B1 (en) * 2014-12-23 2023-05-24 INSERM - Institut National de la Santé et de la Recherche Médicale Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor
WO2016109541A1 (en) * 2014-12-29 2016-07-07 Academia Sinica Method for treating influenza a virus infection
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
AU2018240029A1 (en) * 2017-03-22 2019-10-17 Research Corporation Technologies, Inc. Engineered stable CH2 polypeptides
WO2018181638A1 (ja) * 2017-03-29 2018-10-04 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
CA3062418A1 (en) * 2017-05-06 2018-11-15 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
JP7219265B2 (ja) * 2017-08-24 2023-02-07 フェインズ セラピューティクス，インコーポレーテッド 抗アペリン抗体及びその使用
GB201805675D0 (en) * 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
US20230242672A1 (en) * 2020-06-25 2023-08-03 Gliknik Inc. Ace2-fc fusion proteins and methods of use
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
DE69838986T2 (de) 1997-12-24 2009-01-08 Takeda Pharmaceutical Co. Ltd. Polypeptide, deren herstellung und verwendung
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
AU2001296023A1 (en) * 2000-10-30 2002-05-15 Takeda Chemical Industries Ltd. Process for producing peptide
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DE60211329T2 (de) 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7450586B2 (en) * 2003-07-22 2008-11-11 Motorola, Inc. Network header compression arrangement
JP2008504012A (ja) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
WO2007072980A1 (ja) 2005-12-20 2007-06-28 Takeda Pharmaceutical Company Limited アペリンの新規用途
WO2008147143A2 (en) * 2007-05-30 2008-12-04 Postech Academy-Industry Foundation Immunoglobulin fusion proteins
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
CN103396474A (zh) 2008-11-04 2013-11-20 安科治疗公司 Apj受体化合物
JP2012518398A (ja) * 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US9174428B2 (en) * 2009-08-10 2015-11-03 Corning Incorporated Roll mechanics for enabling printed electronics
HUE032166T2 (en) 2009-11-02 2017-09-28 Univ Washington Therapeutic nuclease preparations and methods
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CA2806252C (en) * 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
US8881594B2 (en) * 2011-03-06 2014-11-11 Alexander Henry Slocum Tapered spiral bellows pressure sensor
PT3045183T (pt) 2011-03-11 2018-11-02 Genzyme Corp Apelina peguilada e suas utilizações
CN103458910A (zh) 2011-03-31 2013-12-18 株式会社资生堂 潮热抑制剂
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
CN106931333B (zh) * 2011-11-23 2020-11-27 夸克星有限责任公司 发光装置
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN102675470B (zh) * 2012-04-01 2015-06-17 江苏省弗泰生物科技有限公司 SCF-Fc融合蛋白
JP6426107B2 (ja) * 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
SG11201506335YA (en) 2013-03-14 2015-09-29 Regeneron Pharma Apelin fusion proteins and uses thereof
MA39061A1 (fr) 2013-11-20 2017-10-31 Regeneron Pharma Modulateurs d'aplnr et leurs utilisations

Also Published As

Publication number Publication date
MX2015011350A (es) 2016-01-15
EA201591700A1 (ru) 2015-12-30
AU2014236451A1 (en) 2015-10-15
HK1220466A1 (zh) 2017-05-05
WO2014152955A1 (en) 2014-09-25
EP2970415A1 (en) 2016-01-20
KR20150127596A (ko) 2015-11-17
JP2016513733A (ja) 2016-05-16
US9751921B2 (en) 2017-09-05
ZA201505927B (en) 2017-03-29
JP6525951B2 (ja) 2019-06-05
CA2904731A1 (en) 2014-09-25
SG11201506335YA (en) 2015-09-29
US20180030099A1 (en) 2018-02-01
US9353163B2 (en) 2016-05-31
EP2970415B1 (en) 2018-12-19
IL240587A0 (en) 2015-09-24
US20140275489A1 (en) 2014-09-18
BR112015020587A2 (pt) 2017-10-10
AU2014236451B2 (en) 2018-08-09
ES2708957T3 (es) 2019-04-12
CN105026423A (zh) 2015-11-04
US20160237130A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
MX365551B (es) Proteinas de fusion de apelina y usos de estas.
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2016008540A (es) Variantes de region fc con propiedades de union al receptor fc neonatal (fcrn).
MX2016011580A (es) Dominios de fibronectina tipo iii que se unen a albumina de suero.
MY172997A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12017500892A1 (en) Antigen binding molecules comprising a tnf family ligand trimer
PT3265478T (pt) Proteínas de fusão compreendendo uma proteína de ligação e um polipéptido de interleucina-15 tendo uma afinidade reduzida por il15ra e utilizações terapêuticas das mesmas
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
MY171407A (en) New polypeptides
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
WO2018050902A3 (en) Multimers, tetramers & octamers
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
MX2020002977A (es) Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
WO2012075318A3 (en) Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
MX2013014008A (es) Anticuerpo que se aglutina a un polipeptido del transportador a1 del casete de aglutinacion a adenosin trifosfato (atp) (abca 1).

Legal Events

Date Code Title Description
FG Grant or registration